SCHEMBL26100863

SCHEMBL26100863

CCOC(=O)c1cnc2c(N(C)Cc3ccc(OC)cc3)cc(Nc3cccc(-c4ccc(C5OCCO5)cn4)c3OC)nn12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 2/20 0.33
▸ TYK2 P29597 4/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA2B P29275 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ PDE4D Q08499 1/20 0.32
▸ POLB P06746 2/20 0.32
▸ APEX1 P27695 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ CTDSP1 Q9GZU7 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ PDE1B Q01064 1/20 0.31
▸ P2RX7 Q99572 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30392554 1.00 FAAH (0.33) FAAHTYK2ADORA3ADORA2AADORA2B
SCHEMBL30392519 0.92 TYK2 (0.34) TYK2PDE4DPDE1BJAK1
SCHEMBL26098936 0.92 TYK2 (0.34) TYK2PDE4DPDE1BJAK1
SCHEMBL26101733 0.92 TYK2 (0.35) TYK2PDE4DPDE1BJAK1
SCHEMBL30392414 0.92 TYK2 (0.35) TYK2PDE4DPDE1BJAK1
SCHEMBL26097378 0.92 TYK2 (0.33) TYK2PDE4DPDE1B
Potassium SCHEMBL30392983 0.92 TYK2 (0.33) TYK2PDE4DPDE1B
SCHEMBL26101583 0.90 TYK2 (0.37) TYK2PDE4DPDE1BJAK1
SCHEMBL30391456 0.90 TYK2 (0.37) TYK2PDE4DPDE1BJAK1
SCHEMBL30392961 0.89 FAAH (0.37) FAAHTYK2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A FAAH 3185/4885TYK2 1/4885ADORA3 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback